In AML, previous studies have reported recurrent mutations in genes such as ASXL1, DNMT3A, FLT3-ITD, IDH1/2, NPM1, TET2, WT1, and MLL-PTD, which impact prognosis and clinical outcomes (1, 12, 13). This evidence concerns the gene DNMT3A and acute myeloid leukemia.